Vaxart stock price forecast vaxart’s share price forecast also

Vaxart’s share price forecast also incorporates Nasdaq biotech sentiment indicators, showing minor bullish divergence, which historically precedes 5–10% short-term gains in microcaps. We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. See our leaderboard of companies with the largest price target upside. Vaxart’s mid-term price forecast shows likelihood of returning toward $1.00 if sector momentum holds and regulatory news leans favorable. Downside risk remains tied to capital raise announcements.